Galena's (GALE) GALE-401 More Promising Following Presentation Phase 2 Data at ASH - Roth
Tweet Send to a Friend
Roth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following presentation of early data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
